Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Lonodelestat (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Santhera Pharmaceuticals
- 22 Sep 2021 Status changed from recruiting to completed.
- 13 May 2021 This trial has been completed in Germany (End Date: 30 Dec 2020), according to European Clinical Trials Database record.
- 13 May 2021 This trial has been completed in Germany (End Date: 30 Dec 2020), according to European Clinical Trials Database record.